Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658775 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1069

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroesophageal Reflux Disease (GERD)

Interventions

DRUG: Rabeprazole sodium
DRUG: Esomeprazole

Sponsor

Eisai Inc.